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Abstract
West Nile (WN) and St. Louis encephalitis (SLE) viruses can cause fatal neurological infection and currently there is neither a
specific treatment nor an approved vaccine for these infections. In our earlier studies, we have reported that siRNAs can be
developed as broad-spectrum antivirals for the treatment of infection caused by related viruses and that a small peptide
called RVG-9R can deliver siRNA to neuronal cells as well as macrophages. To increase the repertoire of broad-spectrum
antiflaviviral siRNAs, we screened 25 siRNAs targeting conserved regions in the viral genome. Five siRNAs were found to
inhibit both WNV and SLE replication in vitro reflecting broad-spectrum antiviral activity and one of these was also validated
in vivo. In addition, we also show that RVG-9R delivers siRNA to macrophages and dendritic cells, resulting in effective
suppression of virus replication. Mice were challenged intraperitoneally (i.p.) with West Nile virus (WNV) and treated i.v. with
siRNA/peptide complex. The peritoneal macrophages isolated on day 3 post infection were isolated and transferred to new
hosts. Mice receiving macrophages from the anti-viral siRNA treated mice failed to develop any disease while the control
mice transferred with irrelevant siRNA treated mice all died of encephalitis. These studies suggest that early suppression of
viral replication in macrophages and dendritic cells by RVG-9R-mediated siRNA delivery is key to preventing the
development of a fatal neurological disease.
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Introduction
West Nile (WN), Japanese B encephalitis (JE) and St. Louis
encephalitis (SLE) viruses are mosquito-borne flaviviruses that can
cause a devastating acute neurological illness with up to 30%
mortality and permanent neurological disabilities in the survivors
[1]. There has been a steady increase in the number of WNV
infections in the US since it first appeared in 1999 [2,3,4]. WNV
has been classified as potential category B bioterrorism agent by
NIAID and there is no effective treatment for this infection. The
recently emerging RNA interference (RNAi) technology appears
to have a great potential in antiviral therapeutics (reviewed in
[5,6,7]. However, currently the major limitation for therapeutic
use of siRNA is the short serum half-life and poor cellular uptake
of siRNA [8]. Thus, delivering effective quantities of siRNAs into
the right target cells in vivo through clinically feasible methods
represents a major challenge for the successful development of
RNAi-based therapeutics [9]. Our recent studies suggest that a
small peptide derived from the rabies virus glycoprotein fused to a
highly positively charged 9-mer polyarginine residues (RVG-9R)
can provide a tool for siRNA delivery to neuronal cells as well as
macrophages [10,11]. Intravenous injection with RVG-9R-
complexed siRNA in mice could reduce the LPS induced TNF-
a production by macrophages in blood as well as by microglia in
the brain, leading to a significant reduction in neuronal apoptosis
[11]. Since flaviviruses are thought to first multiply in dendritic
cells and macrophages before spreading to the brain [12,13,14] in
this study we tested if RVG-9R is able to deliver siRNA to
macrophages to suppress the early virus replication in these cells.
In addition, to expand the repertoire of broad-spectrum siRNAs
capable of suppressing multiple flaviviruses, we also tested a panel
of 25 siRNAs targeting relatively conserved genomic regions.
Results
Identification of broad-spectrum antiflaviviral siRNAs
We have previously shown that a siRNA (FVE
jw) targeting
highly conserved region in the viral envelope gene could inhibit
the replication of both JEV and WNV [15]. However, it has been
suggested that instead of a single siRNA, using a combination of
2–3 siRNAs targeting multiple genomic regions may be ideal to
enhance efficacy and reduce viral escape as well as off-target
effects [16]. Thus, to identify additional siRNAs with broad-
spectrum antiviral activity, we tested 25 siRNAs targeting highly
conserved regions (Table 1) in the flaviviral genome. We first
tested all 25 siRNAs for inhibition of WN infection using FVE
jw
siRNA described earlier as positive control. BHK-21 cells were
transfected with individual siRNAs using lipofectamine reagent
24 h before challenge with WNV and tested for virus replication
72 h after challenge by FACS analysis using anti-West Nile Virus/
Kunjin envelope specific monoclonal antibody (clone 3.67G,
Chemicon) as described earlier [15]. Out of these 25 siRNAs, 5
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if these siRNAs are also effective when introduced postinfection,
BHK-21 cells were first infected with WNV followed 24 h later
with siRNA transfection and analyzed for virus replication 72 h
later. As shown in Fig. 1b, all 5 siRNAs inhibited viral replication
to varying degrees with the best efficacy of 80% inhibition seen
with si2, si6 and si11 siRNAs. The 5 effective siRNAs were also
tested for broad-spectrum antiviral activity. Since the target
regions are also conserved in the SLE, we tested the siRNAs for
protection against SLE infection. As shown in Fig. 1c, 60–80%
inhibition of SLE virus replication was seen with these siRNAs.
Thus, the 5 siRNAs constitute siRNAs with broad-spectrum
antiviral activity effective across at least two viral species.
In vivo efficacy of siRNAs
We selected two siRNAs, si6 and si11 for testing their ability to
suppress WN and SLE infection in vivo. Si6 targets the WNV NS5
gene, whereas Si11 targets the WNV core protein C. We have
previously reported that intravenous delivery of siRNA complexed
with RVG-9R can protect mice from JEV-induced encephalitis.
Thus we used the same system to test effectiveness against WN
infection. Unlike wild type mice, immunodeficient mice including
B-cell-deficient mice are uniformly susceptible to peripheral
infection with flaviviruses [17]. Thus, after confirming that
intraperitoneal infection with our B956 strain of WNV induces
100% mortality in B cell-deficient mice, we tested the treatment
with si6 and si11. We infected groups of B cell-deficient mice (10
mice/group) with WNV intraperitoneally and treated them with iv
injection of RVG-9R/siRNA complex. The test and the control
irrelevant luciferase siRNAs (50 mg/dose/mouse) were adminis-
tered 15 hours before infection, the siRNA treatment repeated 6
and 24 hours after infection (a total of 3 injections) and the mice
were observed for survival for 25 days. All mice treated with the
control siRNA/RVG-9R developed a typical neurologic disease
and died within 9 days showing that the irrelevant siRNA or
RVG-9R has no influence on the course of the disease. In sharp
contrast, 80% of mice treated with si6/RVG-9R were protected,
with mice living without sickness during the entire course of
observation for 25 days (Fig. 2a). The mice treated with si11/
RVG-9R showed only partial protection in that they showed a
delay in the development of disease but all mice died by 13 days.
Next we tested si6 for protection against SLE infection, with
infection and siRNA treatment done as described earlier. Similar
to the results seen with WNV infection, si6 siRNA treatment
showed nearly 80% protection (Fig. 2b). Thus, si6 siRNA appears
to have broad-spectrum antiviral activity in vitro and in vivo.
Although siRNA treatment started before infection was protective,
when the treatment was initiated 2 days after infection, it failed to
afford any protection (Fig. 2c), suggesting that suppression of early
viral replication is important to prevent the neuronal disease. We
also confirmed that si6 and si11 siRNAs do not induce interferon
response both in vitro and in vivo. For this, Raw 264.7 cells were
treated with siRNAs or as positive control, poly (I:C) and 4 h later,
the cellular RNA was tested for upregulation of IFN b, OAS-1,
Table 1. Details of siRNAs targeting conserved regions of West Nile virus.
siRNA designation Guide strand sequence Region in WNV genome Nt position
Si-01 ucgcauuccguuguguuuudTdT Env 2980–2996
Si-02 accgcguuuuagcauauugdTdT Core 138–156
Si-03 ccgcguuuuagcauauugadTdT Core 137–155
Si-04 ccuagcauccauccaaucgdTdT Pre M 886–902
Si-05 gcguuuuagcauauugacadTdT Core 135–153
Si-06 ugacucuccaaugucacagdTdT NS5 8103–8121
Si-07 caguugaagcuguaugccgdTdT Pre M 958–974
Si-08 aaugcuccccuuuccaaacdTdT Env 1287–1305
Si-09 cugugugauccaggacauudTdT NS1 2323–2340
Si-10 augcuccccuuuccaaacadTdT Env 1286–1304
Si-11 cgcguuuuagcauauugacdTdT Core 136–154
Si-12 cguuuuagcauauugacaadTdT Core 135–152
Si-13 augugucaaugcuccccuudTdT Env 1294–1312
Si-14 gugaagguguucagggcaudTdT NS5 9502–9518
Si-15 ucaaugcuccccuuuccaadTdT Core 76–94
Si-16 caaugcuccccuuuccaaadTdT Env 1288–1306
Si-17 gugucaaugcuccccuuucdTdT Env 1292–1310
Si-18 ucccugugugauccaggacdTdT Env 2325–2343
Si-19 ugugucaaugcuccccuuudTdT Env 1293–1311
Si-20 ugugugauccaggacauucdTdT Env 2323–2339
Si-21 gacucuccaaugucacagadTdT NS5 8102–8120
Si-22 guuuuagcauauugacaacdTdT Core 135–151
Si-23 cucuccaaugucacagagcdTdT NS5 8100–8118
Si-24 ucuccaaugucacagagcadTdT NS5 8099–8117
Si-25 acccaguacaucucaugugdTdT NS5 8320–8336
doi:10.1371/journal.pone.0017889.t001
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were elevated in poly (I:C) treated cells, cells treated with siRNAs
did not show an elevated expression of IFN or interferon inducible
genes (Fig. 2d). To confirm this in vivo, C57BL/6J mice were
treated with poly (I:C) or siRNAs complexed with RVG-9R and
1 h later, their spleen cells were tested for IFN response as
described above. Even in this case, while poly (I:C) elicited IFN
response, siRNAs did not show an elevation of IFN or related
genes (Fig. 2e). Taken together, our results suggest that si6 and si11
siRNAs suppress viral replication by RNAi and not due to an IFN
response.
siRNA delivery to macrophages and dendritic cells is
critical to suppress WNV encephalitis
During WNV infection, the virus is thought to initially replicate
in dendritic cells and macrophages before being seeded into the
brain between day 3–4 after infection and then, rapidly multiples
in the brain cells leading to fulminant encephalitis and death by
day 8–9. We have reported that RVG-9R mediates siRNA
delivery to neuronal cells as well as to macrophages and dendritic
cells [11]. Thus, we tested if siRNA delivery to macrophages/DC
is enough to suppress early virus replication and thereby prevent
neuronal disease. For testing this, we infected mice with WNV ip
and treated iv with si6 or the control siLuc complexed RVG-9R as
describe above. Peritoneal exudate cells harvested on day 3 were
analyzed for infection by FACS analysis after staining with
CD11b, CD11c and anti-West Nile Virus/Kunjin envelope
antibody. As shown in Fig. 3a and b, a majority of CD11b+
macrophages and CD11c+ DC from control mice were infected,
while macrophages and DC from si6 treated mice were largely
protected. We also confirmed protection in peritoneal exudate
macrophages by si6 treatment following SLE infection (Fig. 3c,d).
Next, we immunomagnetically isolated CD11b+ cells from the
peritoneal exudate cells obtained from control and si6 siRNA
treated mice and transferred them to new B cell-deficient hosts to
detect transmission. All mice transferred with macrophages from
control siRNA treated mice developed a neurological disease and
died by day 9 while those transferred with macrophages from si6
treated mice all survived with no illness (Fig. 3e). Moreover, brain
sections stained with WNV envelop antibody revealed absence of
infected cells in mice transferred with CD11b cells from si6 treated
mice, compared to that from the control siLuc treated mice
(Fig. 3f). Thus, RVG-9R-mediated siRNA delivery to macrophag-
es/DC is sufficient to prevent the initial viral replication in these
cells and thereby prevent viral dissemination to the brain.
Discussion
In this study, we have identified several siRNAs with broad-
spectrum antiflaviviral activity and shown that suppression of early
viral amplification in macrophages/dendritic cells is sufficient to
prevent fatal encephalitis.
Several previous studies have shown that siRNAs can effectively
inhibit the replication of several flaviviruses including dengue,
West Nile and Japanese encephalitis viruses in vitro (reviewed in
[6]. One previous study also showed effectiveness in vivo in a
mouse model for West Nile virus using a nonphysiological
hydrodymanic injection [18]. However for actual clinical treat-
Figure 1. Protection against WN and SLE viral infection by various siRNAs in BHK21 cells. a) BHK-21 cells were transfected with indicated
siRNAs using lipofectamine 2000, infected with WNV (1moi) 24 h later and tested for virus replication 72 h after infection by FACS analysis. b) Cells
were first infected with WNV, transfected with indicated siRNAs 24 h later and tested for virus replication as in a). c) Indicated siRNAs were tested for
inhibition of SLE replication as in a). All experiments were done in triplicate in 2 independent experiments and the error bars indicate SD.
doi:10.1371/journal.pone.0017889.g001
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17889Figure 2. Intravenous treatment with antiviral siRNA/RVG-9R complex before infection protects mice against WNV and SLEV
induced encephalitis without inducing an interferon response. Mice were treated intravenously with either control siLuc, or si6 or si11,
complexed with RVG-9R 15 h before infection with 5 LD50 of WNV (a) or SLEV (b), the siRNA treatment repeated 4 and 24 h after infection and
monitored for survival over time. Black solid line represents si11; black broken line, si6; grey solid line, siluc. n=10/group. c) Mice were treated with
the control siLuc (solid black line) or si6 siRNA (broken line) daily from 2–5 days after WN infection and monitored for survival. d) Raw 264.7 cells were
treated with indicated siRNAs complexed with RVG-9R or as positive control, with poly (I:C) and 4 h later, the cellular RNA was tested for upregulation
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siRNA to susceptible cells in vivo. Moreover, since clinical
symptoms often overlap and laboratory diagnosis takes time, it
would be better to design siRNAs with broad-spectrum activity
that can suppress related viruses across species. We have
previously shown that a single siRNA targeting a highly conserved
region in the domain 2 of the envelope protein can suppress
infection with both WN and JE viruses [15]. However, multiple
siRNAs with broad spectrum activity will be desirable for a
number of reasons: a combination of siRNAs targeting multiple
regions reduces the concentration of individual siRNAs and
thereby reduces toxicities induced by off-target effects [16];
multiple siRNAs also reduce the chances of viral escape [19,20];
although many regions in flaviviruses are highly conserved at the
amino acid level, they can differ at nucleotide level and since small
sequence changes can affect RNAi, using multiple siRNAs also
help extend the broad-spectrum activity by covering viral strains
showing small nucleotide differences. We propose that a
combination of FVE
JW siRNA described earlier together with si6
and si11 identified in this study would serve to suppress a panel of
encephalitogenic flaviviruses including WN, JE and SLV. All these
siRNAs have been shown to not induce an interferon response and
thus, makes an RNAi therapy possible.
One major hurdle for in vivo therapy is the lack of physiological
methods for siRNA delivery to appropriate cell types in vivo. Since
encephalogenic flaviviruses such as WN, JE and SLE viruses
initially expand in dendritic cells and macrophages and then
extensively replicate in the brain, ideally siRNA needs to be
delivered to both these cell types. To this end, we have previously
reported that a short peptide derived from the Rabies virus
glycoprotein can bind AchR expressing neuronal cells as well as
macrophages and when fused to 9R peptide, the chimeric RVG-
9R peptide can bind siRNA (by charge interaction) and deliver it
to these cell types. Indeed, iv treatment with FvE
jw siRNA
complexed with RVG-9R was able to protect mice from fatal JEV-
induced encephalitis. However, since RVG-9R delivers siRNA to
both macrophages and neuronal cells, it was unclear as to what
role silencing in macrophages played in preventing encephalitis.
Our results in the present study showing that control macrophages
isolated from WN infected mice initiated a fatal disease in new
hosts while siRNA treated macrophages were not, clearly shows
that initial suppression of viral replication in macrophages is
enough to prevent viral transmission to the brain, although
silencing in the brain cells might confer an added benefit to
suppress any leak through virus that might enter the brain. The
fact that siRNA treatment failed to protect when initiated 2 days
after infection (Fig. 2c) also point to the importance of preventing
initial viral replication in macrophages/dendritic cells, although
inaccessibility of the viral genome for RNAi machinery because of
sequestration in membranous structures might also contribute to
the failure for protection beyond 2 days after infection.
Although our results suggest that inhibiting viral replication in
macrophages is enough to prevent development of a neurological
disease, the exact mechanism how this happens is not clear. It is
possible that in the treated animals, the viral burden does not
reach a level required to cross the blood-brain barrier. However, a
recent study suggests that neutrophils and not macrophages
constitute the major reservoir for the early viral replication [21].
Since neutrophils are also known to express AchR [22] it is
possible that RVG-9R is also capable of delivering siRNA to
neutrophils to suppress viral replication, although this needs to be
formally tested. On the other hand, macrophages are also thought
to act as ‘‘Trojan horses’’ to carry virus into the brain [23]. Thus,
RVG-9R mediated siRNA delivery might both lead to a reduced
circulating viral load as well as prevent infected macrophage
seeding into the brain to suppress the development of a neurologic
disease.
In summary, we have identified individual siRNAs that can
suppress multiple encephalitogenic flavivirus species and shown
that silencing viral replication in DC/macrophages is critical to




GGRRRRRRRRR) peptide was synthesized and purified by
high-performance liquid chromatography at the Tufts University
Core Facility (Boston, MA). In RVG-9R, the carboxy-terminal
nine arginine residues were d-arginines. siRNAs shown in Table 1
for the initial screeing in in vitro studies were synthesized at
Alnylam Pharmaceuticals. Large scale antiviral siRNAs for animal
experiments including si6 and si11 as well as the siRNA targeting
firefly luciferase (siLuc; 59-CUUACGCUGAGUACUUC-
GAdTdT-39) were synthesized at Dharmacon (Lafayette, CO).
siRNA transfection and WNV suppression in vitro
Baby hamster kidney cell line (BHK21) was obtained from
ATCC (Manassas, Virginia, United States) and maintained in
DMEM with 10% FCS. The B956 strain of WNV was obtained
from ATCC, grown, and plaque titrated using BHK21 cells.
BHK21 cells were seeded in 12-well plates at 5610
4 per well for
12–16 h before transfection. Lipid-siRNA complexes were pre-
pared by incubating 150 or 300 pmol of siRNA with Lipofecta-
mine 2000 (Invitrogen, Carlsbad, California, United States)
according to the manufacturer’s instruction. Lipid-siRNA com-
plexes were added to the wells in a final volume of 0.5 ml of
serum-free DMEM. After incubation for 6 h, cells were washed,
and reincubated in DMEM containing 10% FCS, and infected
with WNV 24 h post-transfection or 24 h pre-transfection. The
infection levels were monitored after 72 h by flow cytometry using
anti-West Nile Virus/Kunjin envelope specific monoclonal
antibody (clone 3.67G, Chemicon International, from Millipore,
USA).
Animal experiments for testing siRNA to suppress WNV
and SLE
B cell-deficient mice were purchased from the Jackson
Laboratories and used at 6–8 weeks of age. All mouse experiments
had been approved by the TTUHSC IACUC, and animal
infection experiments were performed in a biosafety level 3 animal
facility at the TTUHSC. To test protection against WNV,
peptide/siRNA complexes (at a peptide to siRNA molar ratio of
10:1) were prepared in 100–200 ml of 5% glucose and injected
intravenously at 50 mg of siRNA per mouse per injection 15 hours
before i.p. infection with WNV or SLE (5LD50/mouse). The IV
siRNA treatment was repeated 6 and 24 h following infection (a
total of 3 injections) and the mice were observed for survival for 25
days.
of IFN b, OAS-1, and STAT-1 mRNAs by qRT-PCR (n=3). e) Mice were iv injected with poly (I:C) or siRNAs complexed with RVG-9R and 1 h later, their
total RNA from spleen cells were tested by qRT-PCR (3 mice/group).
doi:10.1371/journal.pone.0017889.g002
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cells to suppress WNV infection in vivo
B cell-deficient mice were challenged with WNV and treated
with si6 or siLuc complexed RVG-9dR as describe above. Spleen
cells were isolated 3 days after challenged, stained with CD11b or
CD11c antibody (BD Biosciences, USA) and anti-West Nile
Virus/Kunjin envelope specific monoclonal antibody and tested
by flow cytometry. Peritoneal CD11b+ cells were immunomagne-
tically isolated, transferred (i.p.) to new B cell-deficient mice and
monitored for survival.
Immunofluorescence Imaging
Mice brains were isolated, fixed in 4% paraformaldehyde (PFA)
overnight at 4uC, and cryoprotected in a graded series of sucrose
treatment (10%, 20%, and 30%, each overnight at 4uC). Para-
median sagital sections were cut at 25 mm with a cryostat. Tissue
sections were PAP pen applied and preblocked in serum-free
protein block for 30 min at ambient temperature. Sections were
then reacted overnight at 4uC with antibody against WNV
antigen. After three rinses in PBS, sections were reacted with
secondary antibodies conjugated with RPE for 1 hr at ambient
temperature. After three additional rinses in PBS, sections were
then nuclear counterstained with DAPI (Invitrogen) and mounted
in fluorescence mounting medium. Images were acquired in
independent channels with fluorescence microscope (Olympus
BX51WI).
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Figure 3. RVG-9dR delivered siRNA suppresses early WNV replication in macrophages and dendritic cells. Mice were infected with
WNV and either not treated (mock) or treated with the control siLuc or si6 siRNA as in Fig. 2a and 3 days after infection, the peritoneal exudate cells
tested for virus replication in CD11b and CD11c gated cells by flow cytometry. A representative histogram (a) and cumulative data from 3 mice (b) are
shown. Error bars represent SD. c,d) Mice were infected with SLE, treated with control or si6 siRNA and their peritoneal exudate cells examined for
virus infection 3 days after infection as in b. A representative histogram (c) and cumulative data from 3 mice (d) are shown. Error bars represent SD. e)
Immunomagnetically isolated CD11b+ macrophages from mice in Fig. 2a were transferred to new mice ip and the mice followed for survival over
time. Solid black line represents si6 treated mice and broken line indicates siLuc treated mice. f) Photomicrographs of brain sections from mice in
Fig. 3c stained with WNV envelope-specific antibody and DAPI (magnification=20X).
doi:10.1371/journal.pone.0017889.g003
siRNA Suppresses Flaviviral Encephalitis
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17889